Pfizer (PFE) Common Equity (2009 - 2026)

Pfizer (PFE) has 18 years of Common Equity data on file, last reported at $90.4 billion in Q1 2026.

• Quarterly Common Equity changed 0.26% year-over-year to $90.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $90.4 billion (changed 0.26% YoY) and the FY2025 annual result came in at $86.8 billion, down 1.95% from the prior year.
• Common Equity rose to $90.4 billion in Q1 2026 per PFE's latest filing, from $86.8 billion in the prior quarter.
• Across five years, Common Equity topped out at $101.2 billion in Q2 2023 and bottomed at $82.7 billion in Q2 2022.
• The 5-year median for Common Equity is $90.6 billion (2025), against an average of $91.6 billion.
• The widest annual swing landed in 2022, when Common Equity jumped 160.16%; it then slipped 11.4% in 2024.
• Tracing PFE's Common Equity over 5 years: stood at $95.9 billion in 2022, then retreated by 6.91% to $89.3 billion in 2023, then slipped by 0.89% to $88.5 billion in 2024, then retreated by 1.95% to $86.8 billion in 2025, then gained by 4.18% to $90.4 billion in 2026.
• Per Business Quant, the three latest PFE Common Equity figures stand at $90.4 billion (Q1 2026), $86.8 billion (Q4 2025), and $93.1 billion (Q3 2025).

Peer Comparison